These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 15743103)

  • 1. Lanreotide Autogel for acromegaly: a new addition to the treatment armamentarium.
    Ciccarelli A; Daly A; Beckers A
    Treat Endocrinol; 2004; 3(2):77-81. PubMed ID: 15743103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
    Caron P; Beckers A; Cullen DR; Goth MI; Gutt B; Laurberg P; Pico AM; Valimaki M; Zgliczynski W
    J Clin Endocrinol Metab; 2002 Jan; 87(1):99-104. PubMed ID: 11788630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
    Shimatsu A; Teramoto A; Hizuka N; Kitai K; Ramis J; Chihara K
    Endocr J; 2013; 60(5):651-63. PubMed ID: 23337477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
    Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel.
    Cendros JM; Peraire C; Trocóniz IF; Obach R
    Metabolism; 2005 Oct; 54(10):1276-81. PubMed ID: 16154424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Somatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patients].
    Caron P
    Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 3):2S19-24. PubMed ID: 12037499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly.
    Caron P; Cogne M; Raingeard I; Bex-Bachellerie V; Kuhn JM
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):209-14. PubMed ID: 16430722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel).
    Gutt B; Bidlingmaier M; Kretschmar K; Dieterle C; Steffin B; Schopohl J
    Exp Clin Endocrinol Diabetes; 2005 Mar; 113(3):139-44. PubMed ID: 15789272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly.
    Álvarez-Escolá C; Venegas-Moreno EM; García-Arnés JA; Blanco-Carrera C; Marazuela-Azpiroz M; Gálvez-Moreno MÁ; Menéndez-Torre E; Aller-Pardo J; Salinas-Vert I; Resmini E; Torres-Vela EM; Gonzalo-Redondo MÁ; Vílchez-Joya R; de Miguel-Novoa MP; Halperín-Rabinovich I; Páramo-Fernández C; de la Cruz-Sugranyes G; Houchard A; Picó-Alfonso AM;
    Endocrinol Diabetes Nutr (Engl Ed); 2019 May; 66(5):320-329. PubMed ID: 30773338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
    Lucas T; Astorga R;
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):320-6. PubMed ID: 16918950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.
    Chanson P; Borson-Chazot F; Kuhn JM; Blumberg J; Maisonobe P; Delemer B;
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):299-305. PubMed ID: 18248639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic evaluation of lanreotide.
    Hu M; Tomlinson B
    Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1301-12. PubMed ID: 20716034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR.
    Alexopoulou O; Abrams P; Verhelst J; Poppe K; Velkeniers B; Abs R; Maiter D
    Eur J Endocrinol; 2004 Sep; 151(3):317-24. PubMed ID: 15362960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).
    An Z; Lei T; Duan L; Hu P; Gou Z; Zhang L; Durand-Gasselin L; Wang N; Wang Y; Gu F;
    BMC Endocr Disord; 2020 May; 20(1):57. PubMed ID: 32366244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic modeling of the effects of lanreotide Autogel on growth hormone and insulin-like growth factor 1.
    Garrido MJ; Cendrós JM; Ramis J; Peraire C; Obach R; Trocóniz IF
    J Clin Pharmacol; 2012 Apr; 52(4):487-98. PubMed ID: 21551318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Acromegaly in Routine Clinical Practice in Germany, Austria and Switzerland.
    Störmann S; Schopohl J; Bullmann C; Terkamp C; Christ-Crain M; Finke R; Flitsch J; Kreitschmann-Andermahr I; Luger A; Stalla G; Houchard A; Helbig D; Petersenn S
    Exp Clin Endocrinol Diabetes; 2021 Mar; 129(3):224-233. PubMed ID: 33285601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
    Verhelst JA; Pedroncelli AM; Abs R; Montini M; Vandeweghe MV; Albani G; Maiter D; Pagani MD; Legros JJ; Gianola D; Bex M; Poppe K; Mockel J; Pagani G
    Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension.
    Melmed S; Cook D; Schopohl J; Goth MI; Lam KS; Marek J
    Pituitary; 2010; 13(1):18-28. PubMed ID: 19639415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lanreotide Autogel: a review of its use in the management of acromegaly.
    Croxtall JD; Scott LJ
    Drugs; 2008; 68(5):711-23. PubMed ID: 18370450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spotlight on lanreotide Autogel in acromegaly.
    Croxtall JD; Scott LJ
    BioDrugs; 2008; 22(4):275-7. PubMed ID: 18611070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.